Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients

(MedPage Today) -- The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related cardiovascular (CV) events compared with older EGFR inhibitors, a retrospective cohort study from Taiwan...